Results 51 to 60 of about 291 (113)

Somapacitan in children born small for gestational age: a randomized controlled phase 3 trial

European Journal of Endocrinology
Abstract Objective Short stature in children born small for gestational age (SGA) is treated with daily injections of recombinant growth hormone (GH), a significant treatment burden. The objective of this study is to demonstrate the efficacy and safety of once-weekly somapacitan, a long-acting ...
Agnès Linglart, Volker Böttcher, Michael Højby, Kamil Soltysik, Carlos Alberto Longui, Lawrence Silverman, Kenichi Kashimada   +6 more
openaire   +2 more sources

Once-weekly somapacitan in children with Noonan syndrome: randomized controlled phase 3 trial

European Journal of Endocrinology
Abstract Objective Daily growth hormone (GH) injections are indicated for the treatment of short stature in children with Noonan syndrome, which presents a treatment burden for the child and their parents/caregivers.
Alexander A L Jorge, Assunta Albanese, Michael Højby, Kamil Soltysik, Thomas Edouard, Anna Grandone, Michael Tansey, Jun Mori   +7 more
openaire   +3 more sources

Corrigendum: Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation

Frontiers in Endocrinology, 2023
Martin Bidlingmaier, Beverly M.K. Biller, David Clemmons, Jens Otto L. Jørgensen, Hiroshi Nishioka, Yutaka Takahashi, Yutaka Takahashi   +6 more
doaj   +1 more source

Somapacitan, a once‐weekly reversible albumin‐binding GH derivative, in children with GH deficiency: A randomized dose‐escalation trial

Clinical Endocrinology, 2017
SummaryObjectiveTo evaluate the safety, local tolerability, pharmacodynamics and pharmacokinetics of escalating single doses of once‐weekly somapacitan, a reversible, albumin‐binding GH derivative, vs once‐daily GH in children with GH deficiency (GHD).DesignPhase 1, randomized, open‐label, active‐controlled, dose‐escalation trial (NCT01973244 ...
Battelino, Tadej, Rasmussen, Michael Højby, De Schepper, Jean, Zuckerman-Levin, Nehama, Gucev, Zoran, Sävendahl, Lars, Schwitzgebel Luscher, Valérie, Zumsteg, Urs, NN8640-4042 Study Group   +8 more
openaire   +4 more sources

6731 Initial therapeutic effects of weekly growth hormone replacement therapy: somapacitan [PDF]

J Endocr Soc
Abstract Disclosure: S. Fujio: None. R. Makino: None. J. Sugata: None. T. Hanada: None. R. Hanaya: None. Introduction: In Japan, the restriction on the administration of somapacitan, a long-acting growth hormone (GH) analogue, was lifted in December 2022, allowing the drug to be administered to many patients with severe ...
Fujio, S, Makino, R, Sugata, J, Hanada, T, Hanaya, R   +4 more
europepmc   +2 more sources

Seven-year safety and efficacy of somapacitan in children with GH deficiency

Background: Somapacitan is a once-weekly GH treatment that has shown efficacy and safety profiles equivalent to daily GH in children with GH deficiency (GHD). Objective: To investigate long-term safety, efficacy, and treatment burden associated with somapacitan after 7 years (364 weeks) of treatment.
Sävendahl, Lars, Battelino, Tadej, Højby Rasmussen, Michael, Leunbach, Tina, Saenger, Paul, Silverman, Lawrence, Horikawa, Reiko   +6 more
openaire   +1 more source

Somapacitan-Beco: For Adult Human Growth Hormone Deficiency

Journal of Medical Science And clinical Research, 2020
openaire   +1 more source

Can long-acting growth hormone improve adherence in pediatric growth hormone deficiency? [PDF]

Endocrine
Rodaro C, Tamaro G, Fachin A, Nicolardi F, Tommasi S, Tornese G.   +5 more
europepmc   +1 more source

Distinct Glucose Profiles with Daily and Weekly Growth Hormone Therapy Revealed by Continuous Glucose Monitoring. [PDF]

J Endocr Soc
Taguchi T, Kimura K, Tsuji S, Ito S, Takamura S, Shimotatara H, Shimizu N, Kubo H, Hoshiyama A, Hayashi A, Takano K, Miyatsuka T.   +11 more
europepmc   +1 more source

Long-acting GH Use in Patients With Adult GH Deficiency Coexisting With Type 1 Diabetes Mellitus. [PDF]

JCEM Case Rep
Higuchi Y, Bando H, Yamamoto M, Hirota Y, Ogawa W, Fukuoka H.   +5 more
europepmc   +1 more source